Prof. Jonathan G Crowston
Synopsis: Glaucomatous optic neuropathy is the leading cause of irreversible blindness world-wide and much pro- gress has taken place in recent years with respect to the diagnosis and management as well as our understanding of the underlying diseases. Recent evidence from the Mayo Clinic suggests that rates of glaucoma blindness have halved over recent decades. So progress has been made but a number of signiftcant challenges persist. This talk will consider both the recent successes as well as the challenges and opportunities that face researchers, clinicians, and patients impacted by glaucoma.
COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED FOLLOWING A ?TREAT AND EXTEND? PROTOCOL: EFFICACY VARIABLES FROM THE PRE-SPECIFIED 12- MONTH INTERIM ANALYSIS OF THE RIVAL STUDY